Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 709893, 9 pages
http://dx.doi.org/10.1155/2012/709893
Review Article

Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor

1Translational Science and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
2Centro de Investigación Lilly, Eli Lilly and Company, 28108 Alcobendas, Madrid, Spain
3Endocrine Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 31 December 2011; Accepted 24 January 2012

Academic Editor: Matteo Monami

Copyright © 2012 Francis S. Willard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Holst, “Glucagon-like peptide-1: from extract to agent. The claude bernard lecture, 2005,” Diabetologia, vol. 49, no. 2, pp. 253–260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Lovshin and D. J. Drucker, “Incretin-based therapies for type 2 diabetes mellitus,” Nature Reviews Endocrinology, vol. 5, no. 5, pp. 262–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. E. Grigoriadis, S. R. J. Hoare, S. M. Lechner, D. H. Slee, and J. A. Williams, “Drugability of extracellular targets: discovery of small molecule drugs targeting allosteric, functional, and subunit-selective sites on GPCRs and ion channels,” Neuropsychopharmacology, vol. 34, no. 1, pp. 106–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. R. Hoare, “Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors,” Drug Discovery Today, vol. 10, no. 6, pp. 417–427, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. V. P. Jaakola, M. T. Griffith, M. A. Hanson et al., “The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist,” Science, vol. 322, no. 5905, pp. 1211–1217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Warne, M. J. Serrano-Vega, J. G. Baker et al., “Structure of a β1-adrenergic G-protein-coupled receptor,” Nature, vol. 454, no. 7203, pp. 486–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Warne, R. Moukhametzianov, J. G. Baker et al., “The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor,” Nature, vol. 469, no. 7329, pp. 241–244, 2011. View at Google Scholar
  8. V. Cherezov, D. M. Rosenbaum, M. A. Hanson et al., “High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor,” Science, vol. 318, no. 5854, pp. 1258–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Y. Chien, W. Liu, Q. Zhao et al., “Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist,” Science, vol. 330, no. 6007, pp. 1091–1095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shimamura, M. Shiroishi, S. Weyand et al., “Structure of the human histamine H 1 receptor complex with doxepin,” Nature, vol. 475, no. 7354, pp. 65–72, 2011. View at Publisher · View at Google Scholar
  11. C. Koole, D. Wootten, J. Simms et al., “Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening,” Molecular Pharmacology, vol. 78, no. 3, pp. 456–465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. B. Knudsen, D. Kiel, M. Teng et al., “Small-molecule agonists for the glucagon-like peptide 1 receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 937–942, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. K. W. Sloop, F. S. Willard, M. B. Brenner et al., “Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets,” Diabetes, vol. 59, no. 12, pp. 3099–3107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. W. P. Walters and M. A. Murcko, “Prediction of “drug-likeness”,” Advanced Drug Delivery Reviews, vol. 54, no. 3, pp. 255–271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. C. A. Lipinski, “Drug-like properties and the causes of poor solubility and poor permeability,” Journal of Pharmacological and Toxicological Methods, vol. 44, no. 1, pp. 235–249, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, “Molecular properties that influence the oral bioavailability of drug candidates,” Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 2615–2623, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Gronberg, E.-R. Sol, A. Danielsson et al., “A low molecular weight non-peptide antagonist of glucagon-like peptide-1,” Diabetes, vol. 49, supplement 1, p. A251, 2000. View at Google Scholar
  18. E. C. Tibaduiza, C. Chen, and M. Beinborn, “A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37787–37793, 2001. View at Google Scholar · View at Scopus
  19. S. Runge, H. Thøgersen, K. Madsen, J. Lau, and R. Rudolph, “Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain,” Journal of Biological Chemistry, vol. 283, no. 17, pp. 11340–11347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. R. Underwood, P. Garibay, L. B. Knudsen et al., “Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor,” Journal of Biological Chemistry, vol. 285, no. 1, pp. 723–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Kopin and M. Beingorn, WO2004/203310 Methods and Compositions for the Treatment of Metabolic Disorders, 2004.
  22. L. K. Truesdale et al., “US 6,469,021 B1 Non-Peptide Antagonists Of GLP-1 Receptor And Methods Of Use,” U.S. Patent, Editor, Agouron Pharmaceuticals, San Diego, Calif, USA, 2002.
  23. D. R. Gehlert, A. Cippitelli, A. Thorsell et al., “3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2, 6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism,” Journal of Neuroscience, vol. 27, no. 10, pp. 2718–2726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Lau, G. Behrens, U. G. Sidelmann et al., “New β-alanine derivatives are orally available glucagon receptor antagonists,” Journal of Medicinal Chemistry, vol. 50, no. 1, pp. 113–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. Duffy, B. A. Kirk, Z. Konteatis et al., “Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 5, pp. 1401–1405, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Shen, F. Zhang, E. J. Brady et al., “Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 20, pp. 4564–4569, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Sinz, J. Chang, A. R. Lins et al., “Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 23, pp. 7131–7136, 2011. View at Publisher · View at Google Scholar
  28. D. Wootten, J. Simms, C. Koole et al., “Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 2, pp. 540–550, 2011. View at Publisher · View at Google Scholar
  29. M. Teng, L. K. Truesdale, and D. Bhumralkar, WO2000/42026 Non-Peptide GLP-1 Agonists, 2000.
  30. N. Irwin, P. R. Flatt, S. Patterson, and B. D. Green, “Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline,” European Journal of Pharmacology, vol. 628, no. 1–3, pp. 268–273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Teng, M. D. Johnson, C. Thomas et al., “Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 19, pp. 5472–5478, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. R. H. Bahekar, M. R. Jain, A. A. Gupta et al., “Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H-imidazol- 2-ylsulfanyl)quinoxalines and quinoxalin-2-yl isothioureas,” Archiv der Pharmazie, vol. 340, no. 7, pp. 359–366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. H. S. Moon et al., WO2011/122815 A2 Novel Quinoxilane Derivatives, 2011, Edited by WIPO.
  34. M. K. Kim et al., “590-P Orally active small molecule GLP-1R agonist, DA-15864 increases insulin secretion in mice,” in Proceedings of the 70th Scientific Sessions of Annual Meeting of American Diabetes Association, Orlando, Fla, USA, 2010.
  35. S. M. Knudsen et al., “WO2006/003096 Condensed Thiophene Dernatives And Their Use As Cyclic GLP-1 Agonists,” 2006.
  36. D. Chen, J. Liao, N. Li et al., “A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 943–948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. He, H. Su, W. Gao et al., “Reversal of obesity and insulin resistance by a non- peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice,” Plos ONE, vol. 5, no. 12, Article ID e14205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Liu, N. Li, Y. Yuan et al., “Cyclobutane derivatives as novel non-peptidic small molecule agonists of glucagon-like peptide-1 receptor,” Journal of Medicinal Chemistry, vol. 55, no. 1, pp. 250–267, 2012. View at Publisher · View at Google Scholar
  39. J. Liao et al., “US2011/023482 Phenylalanine Derivatives And Their Use As Non-Peptide GLP-1 Receptor Modulators,” U.S.P. Application, Editor, Argusina Inc, San Diego, Claif, USA, 2011.
  40. M. Rao, PCT/US2009/039905 Ligands For The Glp-1 Receptor And Methods For Discovery Thereof, I.P. Application, Editor, TransTech Pharma, 2009.
  41. D. R. Polisetti et al., “PCT/US2010/047661 Solid Compositions Comprising An Oxadiazoanthracene Compound And Methods Of Making And Using The Same, I.P. Application, Editor, TransTech Pharma, 2009”.
  42. A. M. M. Mjallli et al., PCT/US2009/036333 Oxadiazoanthracene Compounds For The Treatment Of Diabetes, I.P. Application, Editor, TransTech Pharm, 2009.
  43. D. R. Polisett, E. Benjamin, J. C. Quada et al., WO2011/031620 Solid Composition Comprising an Oxadiazoanthracene Compound and Methods of Making and Using the Same, 2011.
  44. C. Valcarce et al., “Oral glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes,” in Proceedings of the 4th International Congress on Prediabetes and the Metabolic Syndrome, Madrid, Spain, April 2011.
  45. C. de Graaf, C. Rein, D. Piwnica et al., “Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors,” ChemMedChem, vol. 6, no. 12, pp. 2159–2169, 2011. View at Publisher · View at Google Scholar
  46. S. Schann, S. Mayer, M. Frauli et al., “Sounds of silence: innovative approach for identification of novel GPCR-modulator chemical entities,” in Proceedings of the 238th American Chemical Society National Meeting, Washington, DC, USA, 2009.
  47. Y. Gong, H. G. Cheon, T. Lee, and N. S. Kang, “A Novel 3-(8-Chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenyl acetate skeleton and pharmacophore model as glucagon-like peptide 1 receptor agonists,” Bulletin of the Korean Chemical Society, vol. 31, no. 12, pp. 3760–3764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Kenakin, “Functional selectivity and biased receptor signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 2, pp. 296–302, 2011. View at Publisher · View at Google Scholar
  49. P. Keov, P. M. Sexton, and A. Christopoulos, “Allosteric modulation of G protein-coupled receptors: a pharmacological perspective,” Neuropharmacology, vol. 60, no. 1, pp. 24–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Jorgensen, V. Kubale, M. Vrecl, T. W. Schwartz, and C. E. Elling, “Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 1, pp. 148–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Rajagopal, S. Ahn, D. H. Rominger et al., “Quantifying ligand bias at seven-transmembrane receptors,” Molecular Pharmacology, vol. 80, no. 3, pp. 367–377, 2011. View at Google Scholar
  52. B. Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco- incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Google Scholar · View at Scopus
  53. M. P. Graziano, P. J. Hey, D. Borkowski, G. G. Chicchi, and C. D. Strader, “Cloning and functional expression of a human glucagon-like peptide-1 receptor,” Biochemical and Biophysical Research Communications, vol. 196, no. 1, pp. 141–146, 1993. View at Publisher · View at Google Scholar · View at Scopus